AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 71 min read$RNXT

RenovoRx, Inc. (RNXT) Enrolls First Patient in PRISM-TAMP IIT

RenovoRx, Inc. (RNXT) announced the first patient enrolled in the PRISM-TAMP trial, testing TAMP-delivered gemcitabine for pancreatic cancer. The University of Vermont-sponsored study targets ~10 patients. This follows the Phase III TIGeR-PaC trial.

Original reporting
tradingview.com
Published Oct 7, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 12:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
RenovoRx, Inc. (RNXT) Enrolls First Patient in PRISM-TAMP IIT — source image
Source · tradingview.com
Decision brief

The 30-second read

$RNXTBullishMed
01

Why it matters

First‑in‑human enrollment may set the stage for subsequent data releases that could move the stock.

02

Market read

Early trial enrollment is a catalyst for RNXT, potentially influencing biotech investors.

03

What to watch

Regulatory timeline and competition from other pancreatic cancer therapies.

Relevance 8/10Novelty 8/10Timing: today

Background

RenovoRx is a clinical‑stage biotech focused on targeted drug delivery for cancer.

Company-level read

Ticker impact

$RNXTBullishHigh confidence
Context

RenovoRx announced enrollment of the first patient in its PRISM‑TAMP IIT trial for pancreatic cancer.

Expected impact

potential upside as investors price in successful trial milestones

Evidence & confidence

Early‑stage trial enrollment is a material catalyst for a biotech; market typically reacts positively to forward‑looking clinical progress.

Market effects

Sector

May highlight interest in TAMP delivery platforms across oncology biotech sector.

Regional

Limited to US biotech investors; no broad regional effect.

Global

Minimal global impact beyond niche biotech community.

Counterpoint

What could challenge this read

Trial could face delays or negative data, making the enrollment less meaningful.

Key entities

  • Company
    RenovoRx, Inc.

    Biotech developing TAMP‑delivered gemcitabine.

  • Institution
    University of Vermont

    Sponsor of the PRISM‑TAMP trial.

Read at source← All news

Related articles

OCT 7
$RNXTMedAI 8/10

RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

RenovoRx (Nasdaq: RNXT) announced the first patient has enrolled in the PRISM-TAMP trial, evaluating its TAMP platform for borderline resectable pancreatic cancer. The trial, sponsored by the University of Vermont, aims to assess tumor regression and safety. RenovoRx reported $1.1M in 2025 RenovoCath sales and $909K in Q2 2026. The company expects topline data from its Phase III TIGeR-PaC trial in late 2027.

globenewswire.com2 min
OCT 1
$RNXTMedAI 8/10

RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer

RenovoRx (Nasdaq: RNXT) announced a peer-reviewed publication in Case Reports in Oncology. The study, led by researchers at Hackensack Meridian Health, showed promising results for two locally advanced pancreatic cancer patients treated with the company's TAMP platform and RenovoCath device. The patients experienced tumor responses and reductions in CA 19-9 markers.

globenewswire.com2 min
AUG 31
$RNXTLow

Biotech Stocks At 52-Week Highs - RNXT +12%, BLSM, RVTY, ATRC, BFRI

Several biotech stocks hit 52-week highs on August 28, 2026. RenovoRx (RNXT) rose 12% to $1.68 after positive Phase 3 trial data. BlossomHill (BLSM) reached $20.61, with FDA Fast Track designation for BH-30643. AtriCure (ATRC) hit $49.98, reporting Q2 revenue of $153.6M. Biofrontera (BFRI) climbed to $1.61 with 32.9% product revenue growth. Revvity (RVTY) reached $130.07, raising full-year revenue guidance to $2.83B-$2.86B.

rttnews.com2 min
AUG 25
$RNXTMedAI 8/10

RenovoRx study: About 51% of a chemotherapy drug was extracted at the tumor site

RenovoRx (RNXT) reported peer-reviewed data showing ~51% local drug extraction at the tumor site in a sub-study of its Phase III TIGeR-PaC trial. The study compared intra-arterial gemcitabine (IAG) with intravenous gemcitabine (IVG) in 16 patients with locally advanced pancreatic cancer. IAG resulted in lower systemic exposure and a significant correlation between dFdU levels and CA 19-9 tumor marker reduction. The company reported $1.1M in 2025 sales and $909,000 in Q2 2026 revenue. The stock d

stocktitan.net3 min
AUG 14
$RNXTMed

RenovoRx Q2 Earnings Call Highlights

RenovoRx (NASDAQ:RNXT) reported Q2 gross profit of $766,000 and ~84% gross margin. Operating loss was ~$3.4M and net loss per share was $0.06. Cash fell to ~$9.5M at June 30. The company narrowed FY2026 revenue guidance to $3.75M-$4.25M and expects cash-flow break-even in Q4 2027. Phase III TIGeR-PaC enrollment is complete; initial data expected H2 2027.

yahoo.com6 min